Multiple Sclerosis Clinical Trials in Baltimore, Maryland

6 studies are recruiting for multiple sclerosis in Baltimore, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

   This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland

   Locations

   52 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03816345 on ClinicalTrials.gov

2. Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

   This is a randomized, open-label, parallel, Phase 3 study with 2-arms for treatment. The purpose of this study is to evaluate SC administration of frexalimab every 4 weeks (q4w) compared to IV administration of frexalimab q4w in male and female participants with RMS and nrSPMS (aged 18 to 60 years …

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   Baltimore Veterans Affairs Medical Center- Site Number : 8400163, Baltimore, Maryland

   Locations

   40 in total

   Run by

   Sanofi

   See if you can join NCT07325292 on ClinicalTrials.gov

3. A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

   The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting

   Stage

   Not phased

   Ages

   18 and older

   Site

   TG Therapeutics Investigational Trial Site, Baltimore, Maryland

   Locations

   109 in total

   Run by

   TG Therapeutics, Inc.

   See if you can join NCT06433752 on ClinicalTrials.gov

4. Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

   The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measu…

   Stage

   Phase 2

   Ages

   18 to 60

   Site

   Johns Hopkins University, Baltimore, Maryland

   Locations

   2 in total

   Run by

   Johns Hopkins University

   See if you can join NCT07497399 on ClinicalTrials.gov

5. Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

   Fatigue is a prevalent and disabling symptom in Multiple Sclerosis (MS), affecting up to 90% of patients. Current treatments, including off-label prescriptions of wake-promoting agents, have shown limited effectiveness. Previous research indicates that these agents may be beneficial specifically fo…

   Stage

   Phase 2

   Ages

   18 to 60

   Site

   Johns Hopkins University, Baltimore, Maryland

   Run by

   Johns Hopkins University

   See if you can join NCT06170970 on ClinicalTrials.gov

6. Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

   The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or …

   Stage

   Phase 4

   Ages

   18 to 65

   Site

   Johns Hopkins University, Baltimore, Maryland

   Run by

   Johns Hopkins University

   See if you can join NCT07389590 on ClinicalTrials.gov